Crossject Société Anonyme (FRA:74C)

Germany · Delayed Price · Currency is EUR

1.368

+0.012 (0.88%)

Last updated: Sep 10, 2026, 8:02 AM CET

Market Cap	75.13M -4.6%
Revenue (ttm)	2.57M -37.6%
Net Income	-10.37M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	2.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.368
Previous Close	1.356
Day's Range	1.368 - 1.368
52-Week Range	1.338 - 2.590
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 23, 2026

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for manag... [Read more]

Industry Surgical and Medical Instruments and Apparatus

Founded 2001

Employees 99

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 74C

Financial Performance

In 2025, Crossject Société Anonyme's revenue was 2.57 million, a decrease of -37.59% compared to the previous year's 4.12 million. Losses were -10.37 million, -18.97% less than in 2024.

Financial Statements